Is CVAC or MGNX more profitable?

CureVac has a net margin of 199.92% compared to MacroGenics' net margin of -44.79%. CureVac's return on equity of -23.03% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets CureVac 199.92% -23.03% -19.09% MacroGenics -44.79% -147.80% -28.40%

Does the media prefer CRVS or MGNX?

In the previous week, Corvus Pharmaceuticals and Corvus Pharmaceuticals both had 1 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 1.87 beat MacroGenics' score of 0.31 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MacroGenics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, MGNX or AKTS?

Aktis Oncology has lower revenue, but higher earnings than MacroGenics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MacroGenics $149.50M 1.83 -$74.62M -$1.10 N/A Aktis Oncology $6.50M 166.44 N/A N/A N/A

Does the media favor MGNX or AKTS?

In the previous week, Aktis Oncology had 9 more articles in the media than MacroGenics. MarketBeat recorded 10 mentions for Aktis Oncology and 1 mentions for MacroGenics. Aktis Oncology's average media sentiment score of 1.00 beat MacroGenics' score of 0.31 indicating that Aktis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aktis Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer JBIO or MGNX?

In the previous week, Jade Biosciences had 22 more articles in the media than MacroGenics. MarketBeat recorded 23 mentions for Jade Biosciences and 1 mentions for MacroGenics. Jade Biosciences' average media sentiment score of 0.43 beat MacroGenics' score of 0.31 indicating that Jade Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 7 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral MacroGenics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, MGNX or ALVO?

Alvotech has higher revenue and earnings than MacroGenics. Alvotech is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MacroGenics $149.50M 1.83 -$74.62M -$1.10 N/A Alvotech $588.90M 1.93 $27.92M -$0.25 N/A

Is MGNX or ALVO more profitable?

Alvotech has a net margin of -14.36% compared to MacroGenics' net margin of -44.79%. Alvotech's return on equity of -11.92% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets MacroGenics -44.79% -147.80% -28.40% Alvotech -14.36% -11.92% -7.58%

Does the media prefer MGNX or ALVO?

In the previous week, Alvotech had 11 more articles in the media than MacroGenics. MarketBeat recorded 12 mentions for Alvotech and 1 mentions for MacroGenics. Alvotech's average media sentiment score of 0.84 beat MacroGenics' score of 0.31 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alvotech 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MacroGenics (MGNX) Competitors

$4.32 +0.12 (+2.74%)

As of 02:52 PM Eastern

Compare

MGNX vs. CVAC, CRVS, AKTS, JBIO, and ALVO

Should you buy MacroGenics stock or one of its competitors? MarketBeat compares MacroGenics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MacroGenics include CureVac (CVAC), Corvus Pharmaceuticals (CRVS), Aktis Oncology (AKTS), Jade Biosciences (JBIO), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry.

How does MacroGenics compare to CureVac?

CureVac (NASDAQ:CVAC) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, MacroGenics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

In the previous week, MacroGenics had 1 more articles in the media than CureVac. MarketBeat recorded 1 mentions for MacroGenics and 0 mentions for CureVac. MacroGenics' average media sentiment score of 0.31 beat CureVac's score of 0.00 indicating that MacroGenics is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
MacroGenics	Neutral

17.3% of CureVac shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 13.6% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CureVac currently has a consensus price target of $5.25, indicating a potential upside of 12.66%. MacroGenics has a consensus price target of $5.50, indicating a potential upside of 27.46%. Given MacroGenics' stronger consensus rating and higher probable upside, analysts plainly believe MacroGenics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

CureVac has higher earnings, but lower revenue than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
MacroGenics	$149.50M	1.83	-$74.62M	-$1.10	N/A

CureVac has a net margin of 199.92% compared to MacroGenics' net margin of -44.79%. CureVac's return on equity of -23.03% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
MacroGenics	-44.79%	-147.80%	-28.40%

Summary

CureVac and MacroGenics tied by winning 8 of the 16 factors compared between the two stocks.

How does MacroGenics compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Corvus Pharmaceuticals has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Comparatively, 13.6% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Corvus Pharmaceuticals has higher earnings, but lower revenue than MacroGenics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
MacroGenics	$149.50M	1.83	-$74.62M	-$1.10	N/A

Corvus Pharmaceuticals has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. Corvus Pharmaceuticals' return on equity of -38.92% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
MacroGenics	-44.79%	-147.80%	-28.40%

Corvus Pharmaceuticals currently has a consensus target price of $33.33, indicating a potential upside of 185.05%. MacroGenics has a consensus target price of $5.50, indicating a potential upside of 27.46%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Corvus Pharmaceuticals is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Corvus Pharmaceuticals and Corvus Pharmaceuticals both had 1 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 1.87 beat MacroGenics' score of 0.31 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
MacroGenics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Corvus Pharmaceuticals beats MacroGenics on 9 of the 14 factors compared between the two stocks.

How does MacroGenics compare to Aktis Oncology?

MacroGenics (NASDAQ:MGNX) and Aktis Oncology (NASDAQ:AKTS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

Aktis Oncology has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. Aktis Oncology's return on equity of 0.00% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-44.79%	-147.80%	-28.40%
Aktis Oncology	N/A	N/A	N/A

In the previous week, Aktis Oncology had 9 more articles in the media than MacroGenics. MarketBeat recorded 10 mentions for Aktis Oncology and 1 mentions for MacroGenics. Aktis Oncology's average media sentiment score of 1.00 beat MacroGenics' score of 0.31 indicating that Aktis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aktis Oncology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by company insiders. Comparatively, 3.3% of Aktis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

MacroGenics currently has a consensus price target of $5.50, indicating a potential upside of 27.46%. Aktis Oncology has a consensus price target of $32.50, indicating a potential upside of 60.41%. Given Aktis Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Aktis Oncology is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Aktis Oncology has lower revenue, but higher earnings than MacroGenics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.83	-$74.62M	-$1.10	N/A
Aktis Oncology	$6.50M	166.44	N/A	N/A	N/A

Summary

Aktis Oncology beats MacroGenics on 9 of the 12 factors compared between the two stocks.

How does MacroGenics compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

96.9% of MacroGenics shares are held by institutional investors. 23.1% of Jade Biosciences shares are held by company insiders. Comparatively, 13.6% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Jade Biosciences has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market. Comparatively, MacroGenics has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

Jade Biosciences has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. Jade Biosciences' return on equity of -51.34% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-51.34%	-47.32%
MacroGenics	-44.79%	-147.80%	-28.40%

MacroGenics has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A
MacroGenics	$149.50M	1.83	-$74.62M	-$1.10	N/A

In the previous week, Jade Biosciences had 22 more articles in the media than MacroGenics. MarketBeat recorded 23 mentions for Jade Biosciences and 1 mentions for MacroGenics. Jade Biosciences' average media sentiment score of 0.43 beat MacroGenics' score of 0.31 indicating that Jade Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	7 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
MacroGenics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Jade Biosciences currently has a consensus target price of $47.43, indicating a potential upside of 158.93%. MacroGenics has a consensus target price of $5.50, indicating a potential upside of 27.46%. Given Jade Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Jade Biosciences is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Jade Biosciences beats MacroGenics on 10 of the 16 factors compared between the two stocks.

How does MacroGenics compare to Alvotech?

MacroGenics (NASDAQ:MGNX) and Alvotech (NASDAQ:ALVO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

MacroGenics has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

Alvotech has a net margin of -14.36% compared to MacroGenics' net margin of -44.79%. Alvotech's return on equity of -11.92% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-44.79%	-147.80%	-28.40%
Alvotech	-14.36%	-11.92%	-7.58%

MacroGenics presently has a consensus target price of $5.50, suggesting a potential upside of 27.46%. Alvotech has a consensus target price of $7.60, suggesting a potential upside of 101.81%. Given Alvotech's higher possible upside, analysts clearly believe Alvotech is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Alvotech had 11 more articles in the media than MacroGenics. MarketBeat recorded 12 mentions for Alvotech and 1 mentions for MacroGenics. Alvotech's average media sentiment score of 0.84 beat MacroGenics' score of 0.31 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alvotech	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alvotech has higher revenue and earnings than MacroGenics. Alvotech is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.83	-$74.62M	-$1.10	N/A
Alvotech	$588.90M	1.93	$27.92M	-$0.25	N/A

96.9% of MacroGenics shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by company insiders. Comparatively, 0.5% of Alvotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Alvotech beats MacroGenics on 10 of the 16 factors compared between the two stocks.

Get MacroGenics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGNX vs. The Competition

Export

Metric	MacroGenics	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$274.26M	$8.21B	$6.42B	$12.48B
Dividend Yield	N/A	2.61%	2.69%	5.22%
P/E Ratio	-3.92	15.66	23.85	24.39
Price / Sales	1.83	7.10	520.29	116.29
Price / Cash	N/A	17.10	41.27	57.13
Price / Book	4.90	3.63	10.04	6.74
Net Income	-$74.62M	$224.05M	$3.56B	$337.03M
7 Day Performance	2.49%	0.08%	-1.09%	0.13%
1 Month Performance	N/A	N/A	N/A	-1.67%
1 Year Performance	187.67%	2.77%	28.56%	34.29%

MacroGenics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGNX MacroGenics	2.3034 of 5 stars	$4.32 +2.7%	$5.50 +27.5%	+178.1%	$274.26M	$149.50M	N/A	430	Short Interest Increase
CVAC CureVac	N/A	$4.66 flat	$5.25 +12.7%	N/A	$1.05B	$70.74M	6.47	880
CRVS Corvus Pharmaceuticals	2.4028 of 5 stars	$11.68 -3.4%	$33.33 +185.5%	+181.6%	$1.04B	N/A	N/A	30	Positive News
AKTS Aktis Oncology	2.5394 of 5 stars	$20.20 +3.7%	$32.50 +60.9%	N/A	$1.04B	$8.28M	N/A	76	Analyst Forecast Analyst Revision Gap Up
JBIO Jade Biosciences	2.5284 of 5 stars	$17.77 -4.4%	$47.43 +166.9%	N/A	$1.04B	N/A	N/A	20	News Coverage Analyst Forecast Analyst Revision High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGNX) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MacroGenics (MGNX) Competitors

MGNX vs. CVAC, CRVS, AKTS, JBIO, and ALVO

How does MacroGenics compare to CureVac?

Summary

How does MacroGenics compare to Corvus Pharmaceuticals?

Summary

How does MacroGenics compare to Aktis Oncology?

Summary

How does MacroGenics compare to Jade Biosciences?

Summary

How does MacroGenics compare to Alvotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX vs. The Competition

MacroGenics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MacroGenics (MGNX) Competitors

MGNX vs. CVAC, CRVS, AKTS, JBIO, and ALVO

How does MacroGenics compare to CureVac?

Which has more risk & volatility, CVAC or MGNX?

Does the media prefer CVAC or MGNX?

Do insiders and institutionals have more ownership in CVAC or MGNX?

Do analysts recommend CVAC or MGNX?

Which has better earnings and valuation, CVAC or MGNX?

Is CVAC or MGNX more profitable?

Summary

How does MacroGenics compare to Corvus Pharmaceuticals?

Which has more risk & volatility, CRVS or MGNX?

Do insiders & institutionals have more ownership in CRVS or MGNX?

Which has better valuation & earnings, CRVS or MGNX?

Is CRVS or MGNX more profitable?

Do analysts rate CRVS or MGNX?

Does the media prefer CRVS or MGNX?

Summary

How does MacroGenics compare to Aktis Oncology?

Is MGNX or AKTS more profitable?

Does the media favor MGNX or AKTS?

Do insiders and institutionals believe in MGNX or AKTS?

Do analysts rate MGNX or AKTS?

Which has stronger valuation & earnings, MGNX or AKTS?

Summary

How does MacroGenics compare to Jade Biosciences?

Do institutionals & insiders believe in JBIO or MGNX?

Which has more volatility & risk, JBIO or MGNX?

Is JBIO or MGNX more profitable?

Which has higher valuation & earnings, JBIO or MGNX?

Does the media prefer JBIO or MGNX?

Do analysts prefer JBIO or MGNX?

Summary

How does MacroGenics compare to Alvotech?

Which has more volatility & risk, MGNX or ALVO?

Is MGNX or ALVO more profitable?

Do analysts prefer MGNX or ALVO?

Does the media prefer MGNX or ALVO?

Which has higher valuation and earnings, MGNX or ALVO?

Do institutionals and insiders hold more shares of MGNX or ALVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX vs. The Competition

MacroGenics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools